VP, Medical Affairs - Hematology-Oncology

Position Overview Nurix Therapeutics is seeking a Vice President, Medical Affairs, Hematology‑Oncology to build, expand, and lead a best‑in‑class Medical Affairs organization supporting the company’s transition from a clinical‑stage biotechnology company toward commercialization as its hematology‑oncology portfolio advances into late‑stage clinical development. This executive will provide strategic and operational leadership across the full Medical Affairs function, including medical strategy, field medical, scientific communications, evidence generation, thought leader engagement, medical information, and launch readiness. The role will play a central role in shaping the scientific and medical strategy for Nurix’s targeted protein degradation portfolio and helping define the company’s external scientific leadership in hematologic malignancies. The role will be a key cross‑functional partner to Clinical Development, Commercial, Market Access, Regulatory, Legal, and Compliance as Nurix plans and executes future commercialization activities. This leader will contribute broadly to portfolio strategy, lifecycle planning, and enterprise‑level decision making as a member of the senior leadership team. Key Responsibilities Lead and scale the Medical Affairs function to support the progression of Nurix’s hematology‑oncology programs into late‑stage clinical development and future commercial readiness. Own the overall Medical Affairs strategy for the hematology‑oncology portfolio, ensuring alignment with development plans, portfolio priorities, and corporate objectives. Lead development of the scientific platform and differentiated medical narrative for Nurix hematology‑oncology programs within rapidly evolving treatment landscapes. Partner closely with Clinical Development to shape late‑stage medical strategy, including data generation priorities, scientific narrative, external engagement plans, and lifecycle opportunities. Develop and execute integrated medical plans across field medical, scientific communications, publications, medical education, medical information, insight gathering, and evidence generation. Expand and lead a high‑performing MSL organization focused on credible scientific exchange, compliant insight capture, and strong engagement with key external experts, investigators, and treatment centers. Lead external engagement in hematologic malignancies, including advisory boards, investigator relationships, disease‑area thought leader engagement, and interactions with cooperative groups and broader scientific communities. Serve as a senior medical representative of the company with external experts, investigators, and scientific leaders, helping establish Nurix as a credible scientific leader in hematologic malignancies and targeted protein degradation. Direct publication and scientific communication strategy for key clinical data, congress presentations, medical content, symposia, and educational initiatives. Lead integrated evidence generation strategies spanning registrational support, post‑marketing evidence development, real‑world evidence, health economics and outcomes research, treatment sequencing, and product differentiation opportunities. Partner with Commercial and Market Access to ensure medical strategy informs launch readiness, access planning, scientific platform development, training initiatives, and broader commercialization strategy. Monitor the external hematology‑oncology landscape, including standard‑of‑care evolution, competitor data, treatment guidelines, and emerging scientific trends, and translate insights into actionable medical strategy. Ensure all Medical Affairs activities are conducted in compliance with applicable legal, regulatory, and company standards. Provide medical and scientific leadership to executive governance discussions related to portfolio prioritization, lifecycle strategy, label expansion opportunities, external partnerships, and commercialization readiness. Support global Medical Affairs planning and coordination, including scientific congress strategy, evidence generation activities, and external engagement initiatives across key regions. Qualifications MD, PhD, DO, or PharmD required; oncology/hematology experience 15+ years of biopharmaceutical Medical Affairs experience with significant leadership responsibility, including direct accountability for launch and post‑approval Demonstrated leadership experience supporting late‑stage development and commercialization of hematology‑oncology therapies, including launch planning, scientific positioning, and post‑approval medical strategy. Demonstrated expertise in evidence generation (Phase 3b/4, RWE, HEOR), scientific communications, MSL leadership, and cross‑functional launch planning. Strong understanding of global and US regulatory, compliance, and payer environments related to medical activities and drug promotion. Experience in highly innovative therapeutic platforms, first‑in‑class mechanisms, or rapidly evolving treatment landscapes strongly preferred. Excellent leadership, communication, and collaboration skills, with the ability to operate strategically while remaining hands‑on in a fast‑moving pre‑commercial and launch environment. Demonstrated ability to build and scale high‑performing Medical Affairs organizations in emerging biotechnology or growth‑stage commercial settings preferred. #J-18808-Ljbffr Initial Therapeutics, Inc.